Prevalence of anti-SARS-CoV-2 antibodies in Poznań, Poland, after the first wave of the

COVID-19 pandemic

Dagny Lorent,* Rafał Nowak,* Carolina Roxo, Elżbieta Lenartowicz, Aleksandra

Makarewicz, Bartosz Zaremba, Szymon Nowak, Łukasz Kuszel, Jerzy Stefaniak, Ryszard

Kierzek, Pawel Zmora

Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland (D. Lorent, R.

Nowak, C. Roxo, E. Lenartowicz, A. Makarewicz, B. Zaremba, R. Kierzek, P. Zmora)

Department and Clinic of Tropical and Parasitic Diseases, Poznan University of Medical

Sciences, Poznan, Poland (S. Nowak, J. Stefaniak)

Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland (Ł.

Kuszel)

<u>**Abstract**</u>

A serosurvey of antibodies against severe acute respiratory syndrome coronavirus 2

(SARS-CoV-2) was performed between July and September 2020. Within this study, we found

that 0.93% of the Poznań metropolitan area's population had been exposed to SARS-CoV-2

after the first wave of coronavirus disease 2019 (COVID-19).

After the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 in Wuhan, China, the World Health Organization reported almost 81.5 million confirmed cases of SARS-CoV-2 infections and over 1.8 million deaths related to the virus worldwide in 2020 (1). In 2020, Poland was hit by "two waves" of the pandemic, with 1.3 million confirmed SARS-CoV-2 infections and 28.5 thousand deaths caused by the novel coronavirus (2). Due to the political decisions to test only symptomatic patients (2), unspecific symptoms of COVID-19 (3), and asymptomatic SARS-CoV-2 infections (4), those numbers may be underestimated.

The aims of the present sero-epidemiological study were to estimate the prevalence of SARS-CoV-2 antibodies in the population of the Poznań metropolitan area (Poland) after the first wave of the COVID-19 pandemic, to find the risk factors associated with COVID-19 and to compare the immunoassays in detecting anti-SARS-CoV-2 antibodies.

The Study

We randomly selected and invited 1500 adult (over 18 years old) study participants from approximately 15,000 volunteers living in the Poznań metropolitan area, Poland, who answered the online epidemiological survey. Demographic data, including age, gender and occupation of each participant, were collected. Additionally, we asked volunteers about their current health status, potential flu-like symptoms in the last nine months and behavior during the COVID-19 pandemic, namely compliance with epidemiological recommendations. To estimate the severity of an individual's flu-like symptoms, we developed a scoring system based on subjects' self-assessment answers. If the patient did not show any symptoms, a value of 0 was assigned. Each symptom, such as fever, cough, runny nose, fatigue, muscle and joint pain, sore throat, headache,

diarrhea and loss of smell or taste, was rated as 1, and hospitalization due to the flu-like

symptoms was rated as 5. Additionally, the study participants were asked to compare flu-like

symptoms in the last nine months before the serological test to flu-like symptoms in the previous

years. Symptoms of flu-like illness in the last nine months milder than in the past were graded as

0, the same as 3 and more severe as 5. Based on the total sum of values of individual responses,

study participants were divided into four groups: "symptomatic" (0 points), "mild" (1–5 points),

"moderate" (6–14 points) or "severe" (15–24 points). A similar classification approach was

implemented to assess individuals' compliance with epidemiological recommendations. If the

study participant did not follow any recommendations, a value of 0 was assigned. Each of the

preventive measures, such as face mask use, disinfection and social distance, remote work,

avoiding contact with other people, and avoiding the use of public transport, was rated as 1.

Depending on the total sum of values of individual responses, study participants were divided

into three groups: "non-compliant" (0 points), "at some point" (1–2 points) and "in general" (3–4

points) compliant with epidemiological recommendations.

The blood samples were collected from individuals between July and September 2020 at

the Wielkopolskie Centrum Medycyny Podróży, Poznan, and transferred to the IBCH PAS for

further analysis. In case of positive results for the presence of anti-SARS-CoV-2 IgA or

borderline results for the anti-SARS-CoV-2 IgG, the study participants were asked to come again

within 2–3 weeks and an ELISA analysis was repeated. For five study participants with anti-

SARS-CoV-2 IgG-positive results, we did the follow-up analysis at 10 weeks after the first test.

The presence of IgA and IgG antibodies against SARS-CoV-2 was determined using anti-

SARS-CoV-2 IgA ELISA (EuroImmun) or anti-SARS-CoV-2 IgG ELISA (EuroImmun) assays,

respectively. The chosen immunoassays recognized specific anti-SARS-CoV-2 antibodies

against the spike (S) protein. All anti-SARS-CoV-2 IgG positive-samples were confirmed with

quantitative anti-SARS-CoV-2 IgG immunoblot (Polycheck), which uses the S protein and

phosphorylated nucleocapsid protein (PNC) as antigens.

The categorical variables were presented as counts and percentages, and the

seroprevalence estimates were presented together with 95%CI. The 95%CI of the seroprevalence

was calculated using the hybrid Wilson/Brown method. All statistical analyses were performed

with the GraphPad Prism 9 software.

The study was approved by the Bioethics Committee at the Poznan University of Medical

Sciences, Poznan, Poland (Resolution No. 470/20 from 17th June 2019). In addition, written

informed consent was obtained from each study participant.

In total, 25 of 1500 (1.67%) collected samples were found to be positive for anti-SARS-

CoV-2 IgG antibodies (Table 1). Simultaneously, 60 of 1500 (4.0%) collected samples were

found to be positive for anti-SARS-CoV-2 IgA antibodies, but in any of those cases, we did not

observe IgA to IgG seroconversion (data not shown). The presence of anti-SARS-CoV-2 IgG

antibodies was not confirmed with immunoblot in 11 of 25 samples, mostly among study

participants between 18 and 33 years old, as well as among volunteers with autoimmunological

and respiratory system chronic diseases (Table 1). The highest anti-SARS-CoV-2 IgG

seroprevalence was found among study participants over 65 years old, working in positions

related to constant contact with people (e.g., physicians, nurses, shop assistants, civil servants),

and travelling abroad (Table 1). Others were individuals who did not follow epidemiological

recommendations, persons who had direct contact with SARS-CoV-2, and study participants

with confirmed SARS-CoV-2 infection (Table 2). Additionally, we found that among the tested

study participants, 35% of SARS-CoV-2 infections followed an asymptomatic course (Table 1).

Finally, we observed different levels of anti-SARS-CoV-2 IgG antibodies among the study

participants (Figure 1A), which was not altered significantly within 10 weeks (Figure 1B).

Discussion

To our knowledge, this is the first investigation of SARS-CoV-2 seroprevalence in the

general population in Poland. For many months, the reported novel coronavirus infection cases

and COVID-19-related mortality in Poland were among the lowest in Europe. For example, in

October 2020, there were 91,514 confirmed SARS-CoV-2 cases and 2,513 COVID-19-related

deaths in total, but at the same time, in Spain there were 778,607 confirmed infections and

31,791 deaths in total (1, 5). Our study demonstrates low seroprevalence of SARS-CoV-2 in

Poznan (0.93%), one of the biggest cities in Poland, which, in our opinion, may represent the

situation in the whole country. In comparison, at similar time points, the anti-SARS-CoV-2

seroprevalence in Madrid, Spain, was equal to 13.6% (6); in Geneva, Switzerland, it was 10.8%

(7), and in Tehran, Iran, it was 16.3% (8).

This low percentage of individuals with anti-SARS-CoV-2 antibodies in Poznan may

result from early implementation of public health measures, such as the closing of primary

schools and the so-called deep lockdown in March and April 2020. On the other hand, this

situation ensured that as of September 2020, the Polish population remained largely

immunologically naïve to the virus, which explains the dramatic numbers of cases during the

second wave of the pandemic (2). However, it should be noted that based on the seroprevalence

of 0.93%, it is estimated that approximately 4-fold more infections occurred than were reported

by Polish Ministry of Health. These differences may occur among others from the asymptomatic

110 SARS-CoV-2 infections, not included in the SARS-CoV-2 Polish testing strategy, which

111 according to our study can reach 35% of all cases, while other suggest that even 66-80% of

112 seropositive cases were associated with asymptomatic infection (9, 10). Moreover, it should be

113 noted that our study has several limitations, i.e., sensitivity and specificity of serological tests,

114 which can bias the results.

115  In conclusion, our findings confirm the low SARS-CoV-2 incidence in Poland and the

116 effectiveness of early counter-measures.

118 **Acknowledgments**

119  This work was funded by the National Science Center (Poland), grant UMO-

120 2020/01/0/NZ6/00152. The authors would like to thank Aleksandra Jarmołowicz and Julia

121 Jabłońska from the Institute of Bioorganic Chemistry, Polish Academy of Sciences, for their help

122 with volunteers' phone contact. In addition, the authors are grateful to Katarzyna Wysocka and

123 Danuta Kuczmińska from Wielkopolskie Centrum Medycyny Podróży for their assistance with

124 blood sample collection.

126 **Author Bio**

127  Dagny Lorent is a PhD student in the Institute of Bioorganic Chemistry Polish Academy

128 of Sciences, Poznań, Poland. Her research work focuses on molecular biology of

129 microorganisms and structural biology. Rafał Nowak is a PhD student at the Institute of

Bioorganic Chemistry Polish Academy of Sciences, Poznań, Poland. His research interests

include emerging viruses, virus-host interactions and structural biology.

Footnotes

[*] These authors contributed equally to this article.

References

1. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological

update and weekly operational update. https://www.who.int/emergencies/diseases/novel-

coronavirus-2019/situation-reports

2. Polish Ministry of Health. Coronavirus: information and recommendations.

https://www.gov.pl/web/koronawirus

3. Baj J, Karakuła-Juchnowicz H, Teresinski G, Buszewicz G, Ciesielka M, Sitarz E, et al.

COVID-19: Specific and non-specific clinical manifestations and symptoms: the current

state of knowledge. J Clin Med. 2020;9:1753

4. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2

infection: Invisible yet invincible. Int J Infect Dis. 2020;100:112-116

5. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in

real time. Lancet Infect Dis. 2020;20:533-534

6. Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan MA, Perez-Olmeda M, et

al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based

seroepidemiological study. Lancet. 2020; 396:535-44

7. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al.

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland

(SEROCoV-POP): a population-based study. Lancet. 2020;396:313-9

8. Poutschi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared

A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk

occupational groups across 18 cities in Iran: a population-based cross-sectional study.

Lancet Infect Dis. 2021;24:473-481

9. Rogawski-McQuade ET, Guertin KA, Becker L, Operario D, Gratz J, Guan D, et al.

Assesment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-

19 infection among outpatients in Virginia. JAMA Network Open. 2021;4:e2035234

10. Meyerowitz EA, Richterman A, Bogoch II, Low N, Cevik M. Towards and accurate and

systematic characterisation of persistently asymptomatic infection with SARS-CoV-2.

Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30837-9

Address for correspondence: Pawel Zmora, PhD, Institute of Bioorganic Chemistry Polish

Academy of Sciences, ul. Noskowskiego 12/14, 61-704 Poznan, Poland; email:

pzmora@ibch.poznan.pl

Table 1. Prevalence of anti-SARS-CoV-2 IgG antibodies in Poznań metropolitan area.

Category	Participants	ELISA		Western blot	
		Positive results	Seroprevalence (95%CI)	Positive results	Seroprevalence (95%CI)
Overall					
	1500	25	1.67% (1.13-2.45)	14	0.93% (0.56-1.56)
Gender					
Female	896	14	1.56% (0.93-2.60)	8	0.89% (0.45-1.75)
Male	604	11	1.82% (1.02-3.23)	6	0.99% (0.46-2.15)
Age					
18-33	623	10	1.61% (0.87-2.92)	5	0.80% (0.34-1.87)
34-49	606	11	1.82% (1.02-3.22)	7	1.16% (0.56-2.37)
50-65	194	2	1.03% (0.18-3.68)	0	0.00% (0.00-1.94)
65+	77	2	2.60% (0.46-8.99)	2	2.60% (0.46-8.99)
Chronic diseases (CD)					
None	964	16	1.66% (1.02-2.70)	11	1.14% (0.64-2.03)
Circulatory system CD (i.e., hypertension)	185	1	0.54% (0.03-3.00)	1	0.54% (0.03-3.00)
Respiratory system CD (i.e., asthma)	78	3	3.85% (1.05-10.71)	0	0.00% (0.00-4.69)

Infectious CD (i.e., HIV/AIDS)	8	0	0.00% (0.00-32.44)	0	0.00% (0.00-32.44)
Chronic kidney disease	1	0	0.00% (0.00-94.87)	0	0.00% (0.00-94.87)
Digestive track CD (i.e., Crohn disease)	23	0	0.00% (0.00-14.31)	0	0.00% (0.00-14.31)
Autoimmunological diseases (i.e., rheumatoid arthritis)	170	4	2.35% (0.90-5.76)	1	0.59% (0.03-3.26)
Neoplasmatic diseases	5	0	0.00% (0.00-43.45)	0	0.00% (0.00-43.45)
Metabolic diseases (i.e., diabetes)	50	1	2.00% (0.10-10.50)	1	2.00% (0.10-10.50)
Mental disorders (i.e., depression)	29	0	0.00% (0.00-11.70)	0	0.00% (0.00-11.70)

Severity of flu-like illness in the last 9 month before serological tests

No symptoms	260	8	3.08% (1.57-5.95)	5	1.92% (0.82-4.42)
Mild symptoms	454	5	1.10% (0.42-2.30)	4	0.88% (0.34-2.24)
Moderate symptoms	720	12	1.67% (0.96-2.89)	5	0.69% (0.30-1.62)
Severe symptoms	66	0	0.00% (0.00-5.50)	0	0,00% (0.00-5.50)

Test for the presence of SARS-CoV2

Positive	7	3	42.86% (15.82-74.95)	3	42.86% (15.82-74.95)
Negative	349	8	2.29% (1.17-4.46)	6	1.72% (0.79-3.70)

No test	1144	14	1.22% (0.73-2.04)	5	0.44% (0.19-1.02)

    Table 2. Anti-SARS-CoV-2 IgG seroprevalence and COVID19 risk factors.

Category	Participants	ELISA		Western blot	
		Positive results	Seroprevalence (95%CI)	Positive results	Seroprevalence (95%CI)
Occupation related to constant contact with people (i.e., physicians, nurses, shop assistants, civil servants)					
Yes	749	11	1.47% (0.82-2.61)	9	1.20% (0.63-2.27)
No	751	14	1.86% (1.11-3.11)	5	0.67% (0.29-1.55)
Travelling abroad in the last 9 months					
Yes	547	16	2.93% (1.81-4.70)	8	1.46% (0.74-2.86)
No	953	9	0.94% (0.50-1.78)	6	0.63% (0.29-1.37)
Compliance with epidemiological recommendations (i.e. remote work, wearing a mask covering nose and mouth, avoiding contact with other people, avoiding the use of public transport)					
No	46	1	2.17% (0.11-11.33)	1	2.17% (0.11-11.34)
At some point	405	6	1.48% (0.68-3.19)	4	0.99% (0.39-2.51)
Yes, in general	1049	18	1.72% (1.09-2.70)	9	0.86% (0.45-1.62)
Contact with SARS-CoV2 infected person					
Yes	40	2	5.00% (0.85-15.79)	2	5.00% (0.89-16.50)
No	375	7	1.87% (0.91-3.80)	5	1.33% (0.57-3.08)

I don't know	1085	16	1.47% (0.91-2.38)	7	0.65% (0.31-1.33)

176   Figure 1. Anti-SARS-CoV-2 antibodies levels among volunteers. (A) The total levels of anti-

177   SARS-CoV-2 phosphorylated nucleoprotein (PNC) and anti-SARS-CoV-2 spike (S) antibodies

178   among study participants. (B) The changes in the anti-SARS-CoV-2 PNC (left) and anti-SARS-

179   CoV-2 S (right) antibodies levels within 10 weeks in five study participants.

Figure 1

A)

B)